This is a dose-escalation Phase 1 study designed to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose, and the safety profile of CDX-0158 in patients with KIT-positive advanced solid malignancies refractory to standard therapy or for which no standard therapy exists.
Name: CDX-0158 (formerly known as KTN-0158)Description: Single agent CDX-0158 until unacceptable toxicity or progressive diseaseType: Biological
Single Group Assignment
There is one SNP
If documented to have SDH deficient or PDGFRA-D842V GIST, no prior therapy is required for study entry. --- D842V ---